BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Memento EPFL//
BEGIN:VEVENT
SUMMARY:Can Financial Engineering Cure Cancer?
DTSTART:20210604T103000
DTEND:20210604T120000
DTSTAMP:20260509T191308Z
UID:24aeb4ce943692584163cf963dbe61ea90874411f8a4260bc37ea9ef
CATEGORIES:Conferences - Seminars
DESCRIPTION:Andrew W. LO\, MIT\nFunding for early-stage biomedical innovat
 ion has been declining at the same time that medical breakthroughs seem to
  be occurring at ever increasing rates. One explanation for this counterin
 tuitive trend is that increasing scientific knowledge can actually lead to
  greater economic risk for investors in the life sciences. While the Human
  Genome project\, high-throughput screening\, genetic biomarkers\, and gen
 e therapies have been tremendously positive for clinicians and their patie
 nts\, they have also increased the cost and complexity of the drug develop
 ment process\, causing investors to shift their assets to more attractive 
 investment opportunities.  However\, the tools of financial engineering
 —portfolio theory\, securitization\, credit default swaps\, and other co
 mmonly used financial techniques—can be used to reduce the risk and incr
 ease the attractiveness of biomedical innovation so as bring new therapies
  to patients faster.
LOCATION:Zoom
STATUS:CONFIRMED
END:VEVENT
END:VCALENDAR